MAZE Maze Therapeutics, Inc. Insider Trading

CEO Jason V Coloma sells 34,501 shares for $1,034,252.88 under pre-arranged 10b5-1 plan at MAZE

Jason V Coloma, CEO of Maze Therapeutics, executed 3 separate sales totaling 34,501 shares for $1,034,252.88 on 2026-07-01, reducing his holdings by -10.7% versus pre-transaction levels. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, meaning it was scheduled rather than discretionary. The company remains unprofitable with net income of $-24,208,000.00 against revenue of $20,000,000.00, and the stock is currently -41.7% from its 52-week high of $53.65. The CEO has executed sales at this same ticker on five prior occasions dating back to 2026-05-22, with recent activity on 2026-06-22 and 2026-06-23, suggesting a pattern of regular liquidation under the established trading plan rather than a signal tied to discretionary conviction.

CEO Jason V Coloma sold 27,858 shares for $725,494.63 via scheduled 10b5-1 plan at MAZE.

CEO Jason V Coloma executed 3 separate sales totaling 27,858 shares for $725,494.63 on 2026-06-22 and 2026-06-23 at an average price of $26.04, reducing his holdings by 8.0% to 319,079 shares. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, meaning it was scheduled rather than discretionary. At the time of sale, MAZE was trading -50.3% below its 52-week high of $53.65, and the company reported negative net income of $-24,208,000.00 against revenue of $20,000,000.00 in its latest quarter. His prior trades at MAZE (3 separate sells on 2026-05-26, 2026-05-22, and 2026-05-22) showed 30-day returns of -1.2% on the measurable two, though the plan-driven structure removes any inference about timing judgment from this specific filing.

CEO Jason V Coloma sells 32,564 shares for $847,048.18 via pre-arranged 10b5-1 plan; stock down 51.4% from 52-week high, company unprofitable.

Jason V Coloma, CEO of Maze Therapeutics, executed 3 separate sales totaling 32,564 shares for $847,048.18 between 2026-05-22 and 2026-05-26, reducing his holdings by 8.5% from 383,551 shares to 350,987 shares. This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, making it scheduled rather than discretionary. The sales occur in a challenging context: the stock has declined 51.4% from its 52-week high of $53.65 to the current price of $26.05, and the company reported negative net income of $-24,208,000.00 against revenue of $20,000,000.00 in the latest quarter, indicating ongoing unprofitability. The scheduled nature of the plan prevents attribution of timing intent to the CEO, but the magnitude of the decline and persistent losses merit investor attention to the company's path to profitability.

MAZE President of R&D & CMO Bernstein sells entire 15,000-share position for $736,439.29 via 10b5-1 plan

Bernstein, President of R&D & CMO, completed a full liquidation of his 15,000-share stake in Maze Therapeutics across 3 separate sales on 2026-03-20, with transaction prices ranging from $48.20 to $50.02 and a blended average of $49.10. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-29, meaning the sales were scheduled and not discretionary. His post-transaction holding is 0 shares, representing a -100.0% reduction from his pre-transaction position. The complete exit of a senior R&D executive's equity stake warrants monitoring given his direct involvement in the company's clinical and development strategy.

Maze Therapeutics President of R&D Harold Bernstein sells entire 30,000-share position for $1.5M under scheduled 10b5-1 plan

Harold Bernstein, President of R&D & CMO at Maze Therapeutics, sold 30,000 shares through 2 separate transactions on 2026-03-10, raising $1,513,560.22 at a blended average price of $50.45. The sale represents a 100.0% reduction of his holdings, leaving him with 0 shares post-transaction. This divestment is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-29, meaning the sale was scheduled rather than discretionary. As a senior R&D executive, the complete elimination of his equity stake warrants attention to whether this reflects changing employment plans or broader strategy shifts, though the scheduled nature of the trade precludes timing-based inference.

Bernstein (President, R&D & CMO) sold all 15,000 shares for $690,333.75 under pre-arranged 10b5-1 plan

Harold Bernstein completed a scheduled liquidation of his entire equity stake at Maze Therapeutics through 4 separate sales totaling 15,000 shares for $690,333.75, executed on 2026-02-02 under a 10b5-1 trading plan adopted on 2025-09-29. The transaction reduced his holdings from 15,000 shares to zero, representing a complete exit. Because the sales were part of a pre-arranged plan rather than discretionary trading, the timing reflects the plan's predetermined schedule rather than Bernstein's real-time market judgment. The complete elimination of his equity position warrants investor attention regarding retention patterns among senior R&D leadership at the company.

Bernstein (President, R&D & CMO) sold 25,156 shares (25.2K) of MAZE at $40.20; exits all holdings via 10b5-1 plan

Bernstein, the President of R&D and CMO at Maze Therapeutics, completed the full liquidation of his 25,156 shares for $1,011,298.87 on 2026-01-07 at $40.20 per share. This transaction eliminates his entire equity stake in the company and was executed under a 10b5-1 trading plan adopted on 2025-09-29, meaning it was scheduled and not discretionary. The complete exit by a senior R&D executive warrants investor attention, particularly given his direct leadership role in the company's core drug development functions, though the pre-arranged nature of the plan removes any discretionary timing signal.

Director Sohn sold 29,413 shares (entire position) for $1,149,054.36 across 2 transactions; stock up 42.0% in 90 days

Catherine A. Sohn executed 2 separate sales totaling 29,413 shares for $1,149,054.36, divesting her entire position at a blended average price of $39.07 per share on January 6-7, 2026. The stock has appreciated 42.0% over the prior 90 days and currently trades at $38.95, near the top of its 52-week range. Sohn's cross-ticker track record shows 100% win rate on her prior 90-day holds, though with only 2 prior buys, suggesting limited historical data at this specific ticker. Given that Maze is pre-revenue and reporting quarterly net losses of $-30,087,000, the complete liquidation of a director's holdings may merit observation of regulatory filings and company disclosures.

CSBO Dandekar sells 72,500 shares for $2.9M under 10b5-1 plan; retains 10.5K shares post-sale

Dandekar Atul, Chief Science & Business Officer, executed 3 separate sales totaling 72,500 shares for $2,940,799.43 across 2025-12-29 and 2025-12-30 at an average price of $40.56. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-29, meaning the sales were scheduled rather than discretionary. Post-transaction holdings of 10,503 shares represent a -87.3% reduction from the pre-transaction level of 83,003 shares. The scheduled nature of this liquidation under a 10b5-1 plan limits inference about current insider conviction; such plans are established in advance and execute systematically regardless of intervening market conditions or company developments.

President of R&D & CMO Bernstein sells entire 45.0K share position for $1.8M via 10b5-1 plan

Bernstein sold 45,000 shares across 2 separate transactions on 2025-12-29, completely exiting his holdings at a blended average price of $40.56 for total proceeds of $1,825,354.84. This sale was executed under a 10b5-1 trading plan adopted on 2025-09-29, meaning the transactions were scheduled in advance and not driven by discretionary timing decisions. The complete liquidation of a 45,000-share position by an executive holding a significant R&D and CMO role represents a material stake reduction, though the scheduled nature of the plan constrains the inference that can be drawn about his contemporaneous views on valuation.